You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

70 Results
Guidelines and Advice
Status: Current
ID: PET 6
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Mar 2009
Guidelines and Advice
Status: Archived
ID: 3-16
Jul 2009
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Guidelines and Advice
Jan 2009
Drug
Other Name(s): Lupron® , Lupron Depot® , Eligard®
May 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    bicalutamide
May 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025

Pages